<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933240</url>
  </required_header>
  <id_info>
    <org_study_id>HM20021901</org_study_id>
    <nct_id>NCT04933240</nct_id>
  </id_info>
  <brief_title>Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot Trial</brief_title>
  <official_title>Tamoxifen Versus Estradiol in the Prevention of Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the ability of medicines called tamoxifen&#xD;
      or estradiol to prevent annoying vaginal bleeding for arm implant users.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study compares the use of tamoxifen to estradiol to placebo for seven days once a&#xD;
      month up to 5 months in contraceptive implant users starting from the time of implant&#xD;
      initiation. Participants will record bleeding and satisfaction response in a daily text&#xD;
      diary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of bleeding free days</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of days of no spotting or bleeding after initiation of first treatment until day of subsequent bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of bleeding free days</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Total number of no spotting or bleeding days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to first re-treatment</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Number of days between first and second use of medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of re-treatments</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Total number of times participant used treatment medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with bleeding</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Average satisfaction with bleeding will be assess using daily text surveys. Participants will rate degree of satisfaction with bleeding with the use of symbols (emojis): 1) completely unsatisfied, 2) somewhat unsatisfied, 3) neutral, 4) somewhat satisfied, 5) completely satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Affects on daily life activities</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The average affect of bleeding on daily life activities will be assess using daily text surveys. Participants will rate the degree of affects of bleeding on daily life with the use of a visual analogue scale from 0 (no affects) to 100 (highest possible affects)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Vaginal Bleeding</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tamoxifen 10mg daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>estradiol 1mg daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen Citrate 10Mg Tab</intervention_name>
    <description>nonsteroidal antiestrogen for oral administration in 10 mg tablets. Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10 mg of tamoxifen.</description>
    <arm_group_label>Tamoxifen</arm_group_label>
    <other_name>NOLVADEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>estradiol tablets for oral administration contains 1 mg of micronized estradiol per tablet.</description>
    <arm_group_label>Estradiol</arm_group_label>
    <other_name>ESTRACE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A sugar tablet that does not contain any active medicine</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Inactive drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  etonogestrel implant users&#xD;
&#xD;
          -  at time of and/or within 21 days of initial use of etonogestrel implant placement&#xD;
&#xD;
          -  must agree not to take additional hormonal therapy during the study trial period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  within 6 months following vaginal or cesarean delivery&#xD;
&#xD;
          -  within 6 weeks following abortion&#xD;
&#xD;
          -  currently breastfeeding&#xD;
&#xD;
          -  positive pregnancy test&#xD;
&#xD;
          -  contraindications to tamoxifen or estrogen&#xD;
&#xD;
          -  history of thromboembolism&#xD;
&#xD;
          -  undiagnosed abnormal uterine bleeding&#xD;
&#xD;
          -  active cervicitis&#xD;
&#xD;
          -  bleeding disorder&#xD;
&#xD;
          -  use of anticoagulation medications&#xD;
&#xD;
          -  an unwillingness or inability to keep a daily menstrual diary or to follow the study&#xD;
             criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances Casey, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>VCU Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frances E Casey, MD, MPH</last_name>
    <phone>8048284409</phone>
    <email>frances.casey@vcuhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shanthi Ramesh, MD</last_name>
    <phone>8043554358</phone>
    <email>sramesh@vlpp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanthi Ramesh</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23221</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shanthi Ramesh, MD</last_name>
      <phone>804-355-4358</phone>
      <email>sramesh@vlpp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Frances Casey, MD, MPH</last_name>
      <phone>804-828-4409</phone>
      <email>frances.casey@vcuhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mansour D, Fraser IS, Edelman A, Vieira CS, Kaunitz AM, Korver T, Pong A, Lin J, Shah AK, Fox M, Rekers H, Creinin MD. Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first 2 years of use? Contraception. 2019 Oct;100(4):264-268. doi: 10.1016/j.contraception.2019.05.017. Epub 2019 Jun 6.</citation>
    <PMID>31176688</PMID>
  </reference>
  <reference>
    <citation>Edelman AB, Kaneshiro B, Simmons KB, Hauschildt JL, Bond K, Boniface ER, Jensen JT. Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users: A Randomized Controlled Trial. Obstet Gynecol. 2020 Aug;136(2):323-332. doi: 10.1097/AOG.0000000000003896.</citation>
    <PMID>32649493</PMID>
  </reference>
  <reference>
    <citation>Abdel-Aleem H, d'Arcangues C, Vogelsong KM, Gaffield ML, GÃ¼lmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev. 2013 Oct 21;(10):CD003449. doi: 10.1002/14651858.CD003449.pub5. Review.</citation>
    <PMID>24146298</PMID>
  </reference>
  <reference>
    <citation>Abdel-Aleem H, Shaaban OM, Amin AF, Abdel-Aleem AM. Tamoxifen treatment of bleeding irregularities associated with Norplant use. Contraception. 2005 Dec;72(6):432-7. Epub 2005 Aug 9.</citation>
    <PMID>16307966</PMID>
  </reference>
  <reference>
    <citation>DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Taverniti C, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Branchi D, Campora S, Petrera M, Buttiron Webber T, Boni L, Bonanni B. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. J Clin Oncol. 2019 Jul 1;37(19):1629-1637. doi: 10.1200/JCO.18.01779. Epub 2019 Apr 11.</citation>
    <PMID>30973790</PMID>
  </reference>
  <reference>
    <citation>Buzdar AU, Hortobagyi GN, Frye D, Ho D, Booser DJ, Valero V, Holmes FA, Birmingham BK, Bui K, Yeh C, et al. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol. 1994 Jan;12(1):50-4. Erratum in: J Clin Oncol 1994 Jun;12(6):1337.</citation>
    <PMID>8270984</PMID>
  </reference>
  <reference>
    <citation>Macpherson AM, Archer DF, Leslie S, Charnock-Jones DS, Makkink WK, Smith SK. The effect of etonogestrel on VEGF, oestrogen and progesterone receptor immunoreactivity and endothelial cell number in human endometrium. Hum Reprod. 1999 Dec;14(12):3080-7.</citation>
    <PMID>10601100</PMID>
  </reference>
  <reference>
    <citation>Leslie KK, Walter SA, Torkko K, Stephens JK, Thompson C, Singh M. Effect of tamoxifen on endometrial histology, hormone receptors, and cervical cytology: a prospective study with follow-up. Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):284-93.</citation>
    <PMID>17721273</PMID>
  </reference>
  <reference>
    <citation>Archer DF, Philput CA, Weber ME. Management of irregular uterine bleeding and spotting associated with Norplant. Hum Reprod. 1996 Oct;11 Suppl 2:24-30.</citation>
    <PMID>8982742</PMID>
  </reference>
  <reference>
    <citation>Thomas AM, Hickey M, Fraser IS. Disturbances of endometrial bleeding with hormone replacement therapy. Hum Reprod. 2000 Aug;15 Suppl 3:7-17. Review.</citation>
    <PMID>11041216</PMID>
  </reference>
  <reference>
    <citation>Alvarez-Sanchez F, Brache V, Thevenin F, Cochon L, Faundes A. Hormonal treatment for bleeding irregularities in Norplant implant users. Am J Obstet Gynecol. 1996 Mar;174(3):919-22.</citation>
    <PMID>8633669</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

